Haisco Pharma advances 2025 A-share private placement plan

Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) has announced revisions to its 2025 plan for a private placement of A-shares. The company's Fifth Board of Directors and Fifth Board of Supervisors approved the revised draft on April 3, 2025. Key amendments include updates to the fulfillment of decision-making procedures for the targeted A-share issuance, revisions to the definition of terms like "Pre-案/本預案", and updates to information regarding the actual controller and shareholding ratios before and after the issuance. The company also updated the analysis of why the company needs this funding. The company’s directors, senior management and controlling shareholders have also committed to fulfilling measures to ensure the company will perform and improve profits. The proposed private placement is still subject to shareholder approval, Shenzhen Stock Exchange review, and registration with the China Securities Regulatory Commission, and carries investment risks. Detailed information on the proposed issuance and related documents can be found on the Juchao Information Website (www.cninfo.com.cn).